Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Mayne Pharma has officially opened its expanded manufacturing facility in Salisbury, South Australia, which has been modernized with an $18 million investment. The facility, supported by a $4.8 million government grant, enhances production efficiency and capacity, positioning the company for new product launches and exports, and contributing to a 7% revenue increase in FY25.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, primarily in dermatology and women’s health in the United States. The company also provides contract development and manufacturing services globally, with a strong history of innovation in oral drug delivery systems.
Average Trading Volume: 540,993
Technical Sentiment Signal: Sell
Current Market Cap: A$264M
Learn more about MYX stock on TipRanks’ Stock Analysis page.